Linked Life Data

6666224

Source:http://linkedlifedata.com/resource/pubmed/id/6666224

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1984-3-21
pubmed:abstractText
The purpose of this study was to investigate whether the anti-ischemic effects of a single 80-mg tablet of isosorbide dinitrate in sustained-release form are attenuated after 2 weeks of twice-daily administration. In order to follow a double-blind protocol with respect to the 12-h interval, we also evaluated, in randomized order, another group of patients receiving the tablets once daily. Parameters for assessment of the anti-ischemic effects were changes in exercise-induced ST-segment depression and the simultaneously recorded left ventricular ejection fraction, as determined by radionuclide ventriculography. The ST-segment depression was measured completely blind; the left ventricular ejection fraction was calculated automatically with a clinically validated software. In the group that received the tablets once daily (n = 10) none of the patients showed any signs of attenuation of the beneficial anti-ischemic effects. However, seven of the 12 patients who received the tablets twice daily demonstrated significant attenuation. Thus, based on analysis of the presently available studies, in order to guarantee maintenance of the anti-ischemic benefits, a once-daily high dose of ISDN in sustained-release form (80 mg or even higher) is recommended.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-5860
pubmed:author
pubmed:issnType
Print
pubmed:volume
72 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
211-7
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Anti-ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial